加拿大英属哥伦比亚大学Christian Steidl、David W. Scott等研究人员合作发现,TMEM30A功能丧失突变驱动淋巴瘤发生并可作为B细胞淋巴瘤治疗靶点。该项研究成果于2020年2月24日在线发表在《自然—医学》杂志上。
Title: TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
Author: Daisuke Ennishi, Shannon Healy, Ali Bashashati, Saeed Saberi, Christoffer Hother, Anja Mottok, Fong Chun Chan, Lauren Chong, Libin Abraham, Robert Kridel, Merrill Boyle, Barbara Meissner, Tomohiro Aoki, Katsuyoshi Takata, Bruce W. Woolcock, Elena Vigan, Michael Gold, Laurie L. Molday, Robert S. Molday, Adele Telenius, Michael Y. Li, Nicole Wretham, Nancy Dos Santos, Mark Wong, Natasja N. Viller, Robert A. Uger, Gerben Duns, Abigail Baticados, Angel Madero, Brianna N. Bristow, Pedro Farinha, Graham W. Slack, Susana Ben-Neriah, Daniel Lai, Allen W. Zhang, Sohrab Salehi, Hennady P. Shulha, Derek S. Chiu, Sara Mostafavi, Alina S. Gerrie, Da Wei Huang, Christopher Rushton, Diego Villa, Laurie H. Sehn, Kerry J. Savage, Andrew J. Mungall, Andrew P. Weng, Marcel B. Bally, Ryan D. Morin, Gabriela V. Cohen Freue, Louis M. Staudt, Joseph M. Connors, Marco A. Marra, Sohrab P. Shah, Randy D. Gascoyne, David W. Scott, Christian Steidl
Issue&Volume: 2020-02-24
Abstract: Transmembrane protein 30A (TMEM30A) maintains the asymmetric distribution of phosphatidylserine, an integral component of the cell membrane and ‘eat-me’ signal recognized by macrophages. Integrative genomic and transcriptomic analysis of diffuse large B-cell lymphoma (DLBCL) from the British Columbia population-based registry uncovered recurrent biallelic TMEM30A loss-of-function mutations, which were associated with a favorable outcome and uniquely observed in DLBCL. Using TMEM30A-knockout systems, increased accumulation of chemotherapy drugs was observed in TMEM30A-knockout cell lines and TMEM30A-mutated primary cells, explaining the improved treatment outcome. Furthermore, we found increased tumor-associated macrophages and an enhanced effect of anti-CD47 blockade limiting tumor growth in TMEM30A-knockout models. By contrast, we show that TMEM30A loss-of-function increases B-cell signaling following antigen stimulation—a mechanism conferring selective advantage during B-cell lymphoma development. Our data highlight a multifaceted role for TMEM30A in B-cell lymphomagenesis, and characterize intrinsic and extrinsic vulnerabilities of cancer cells that can be therapeutically exploited.
DOI: 10.1038/s41591-020-0757-z
Source: https://www.nature.com/articles/s41591-020-0757-z
Nature Medicine:《自然—医学》,创刊于1995年。隶属于施普林格·自然出版集团,最新IF:30.641
官方网址:https://www.nature.com/nm/
投稿链接:https://mts-nmed.nature.com/cgi-bin/main.plex